Pivotal Phase 3 studies of once-daily oral zasocitinib met all primary and ranked secondary endpoints in patients with moderate-to-severe plaque psoriasisMore than half of study participants treated ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback